Biography
In his research, Stock studies body mechanisms that lead to transplant rejection when the donor and recipient are not genetically identical. He also studies chimerism (a therapy to prevent transplant rejection that uses the donor's bone marrow cells) and pancreatic islet cell transplantation (a procedure that can allow people with type 1 diabetes to discontinue insulin therapy).
Stock received his medical training at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992.
Stock is an active teacher and supervises surgical residents and fellows. He is a member of numerous professional and honorary societies.
Videos
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of California, San Francisco | Post-Doc Fellow/Scholar | Medicine | 1991 |
University of Illinois | M.D. | School of Medicine | 1982 |
University of California, San Francisco | Residency |
Board Certifications
- American Board of Surgery, 1991
Awards & Honors
Award | Conferred By | Date |
---|---|---|
James IVth Fellowship Award | US Representative | 2000 |
Faculty Fellowship Award | American College of Surgeons | 1993 |
Sandoz Fellowship Award | American Society of Transplant Surgeons | 1991 |
Outstanding Surgical Resident Teaching Award | Department of Surgery, University of Minnesota, Minneapolis, MN | 1989 |
David Gaviser Award, Outstanding Surgical Research | University of Minnesota, Minneapolis, MN | 1989 |
Outstanding Research Award, Senior Medical Student | University of Illinois, Chicago, IL | 1982 |
Alpha Omega Alpha | University of Illinois, Chicago, IL | 1981 |
Magna Cum Laude, Honors in Biology with High Distinction | University of Illinois, Urbana, IL | 1978 |
Phi Beta Kappa | University of Illinois, Urbana, IL | 1978 |
Clinical Expertise
Bile Duct Injuries
Bile Duct Strictures
Cholangiocarcinoma (Bile Duct Cancer)
Choledochal Cyst Disease
Dialysis Access
End-Stage Kidney Disease
Fulminant Hepatic Failure
Hepatocellular Carcinoma (Liver Cancer)
Hepatitis B
Hepatitis C
Kidney Transplantation
Kidney and LIver Transplantation in HIV Patients
Liver Transplantation
Living Donor Liver Transplantation
Living Donor Kidney Transplantation
Pediatric Liver Transplantation
Pediatric Kidney Transplantation
Pancreatic Islet Cell Transplantation
Pancreas Transplantation
Polycystic Kidney Disease
Polycystic Liver Disease
Portal Hypertension
Clinical Trials
- Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes (NCT03977662)Related Conditions: Diabetes, Diabetes Type 1| Start Date: | End Date:
- Related Conditions: HIV/AIDS, Kidney Disease, Kidney Transplant, Transplants| Start Date: | End Date:
- Related Conditions: HIV/AIDS, Hepatitis C, Cirrhosis, Fibrosis, Liver Transplant, Hepatitis A, Hepatitis| Start Date: | End Date:
- Related Conditions: HIV/AIDS, Kidney Transplant, Transplants, Liver Transplant| Start Date: | End Date:
- Related Conditions: Diabetes, Diabetes Type 1| Start Date: | End Date:
- Kidney and Liver Transplantation in People With HIV (NCT00074386)Related Conditions: HIV/AIDS, Kidney Disease, Liver Disease, Liver Transplant| Start Date: | End Date:
Program Affiliations
Book Chapters
Zarinsefat A, Stock P. Islet vs. pancreas transplantation in nonuremic patients with type 1 diabetes. Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas. 2020 Jan 1; 417-423.
Stock PG, Mukhtar R, Ghersin H, Fiscalini AS, and Esserman L. Pragmatic Trials and Approaches to Transforming Care. In: Pawlik T.,Sosa J. (eds). Clinical Trials. Success in Academic Surgery. Springer, Cham. 2020 March 11; 59-76. https://doi.org/10.1007/978-3-030-35488-6_6
Locke J, Stock P. Renal Transplantation 7th Ed. Editor(s): Mulholland MW, Lillemoe KD, Doherty GM, Maier RV, Simeone DM, Unchurch Jr GR. G. Greenfield’s Surgery: Scientific Principles and Practice: Lippincott Williams and Wilkens, Philadelphia. In press.
In the News
Grants and Funding
- Filling a Void of Research (FAVOR) Training for Transplant Surgeons | NIH | 2016-08-01 - 2026-07-31 | Role: Principal Investigator
- Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients | NIH | 2015-08-19 - 2022-07-31 | Role: Principal Investigator
- Diabetes Research Center | NIH | 2002-09-01 - 2021-03-31 | Role: Co-Investigator
- Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant | NIH | 2015-01-15 - 2019-12-31 | Role: Principal Investigator
- Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients | NIH | 2013-05-15 - 2015-04-30 | Role: Principal Investigator
- Solid Organ Transplantation in HIV: Multi-Site Study | NIH | 2003-08-15 - 2013-08-31 | Role: Principal Investigator
- General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
Research Narrative
During the last 3 years, the major thrust of my research and creative activities have focused in three areas, which are listed below along with related NIH and extramural funding covering the research since the last advancement (2018):
- Improving the outcomes of solid organ transplantation in people with HIV and translational studies bridging the previously distinct worlds of HIV and transplantation. Related funding during last 3 years: A) NIH U01Al118594-05 – Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients (Stock PI)(active until 07/31/2021); B) NIH U01 Hope in Action Prospective Multi-Center Trial (Stock Site PI)(active until 07/31/3021); C) NIHU01 Al152153-01 – Maximizing the success of HIV+ to HIV+ Kidney Transplantation in South Africa (Stock Co-Investigator)(active until 03/31/2025); D) NIH U01 A1115714-03 Sofusbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant (Stock PI)(funding ended 12/31/19); E) American Foundation for AIDS Research (amfAR) 109119-57-RGRL – Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant (Stock PI)(funding ended 01/31/2018).
- Beta Cell Replacement strategies for the treatment of diabetes mellitus with pancreas transplantation, islet transplantation, or stem cell-derived beta cell clusters. We were funded ($11-million dollar grant) from CIRM to develop the forearm as a site for islet cell transplantation. This novel approach uses co-transplantation of islets with parathyroid tissue to facilitate engraftment – and has the potential for the development of a safe and accessible site for stem cell-derived beta cells. Related funding during last 3 years: A) California Institute for Regenerative Medicine (CIRM) – Islet and PARAthyroid Co-Transplantation for Treatment of Diabetes in Intra-Muscular Site (PARADIGM) (Stock PI) (active until 06/30/2023); B) NIH/NIDDK P30 DK063720 Diabetes Endocrinology Research Center (Stock Director of the Islet Production Core, German PI) (funding end 03/31/2020, renewal pending).
- Public Policy/Organ Allocation: During the last 3 years, I continue to have an active role in the development of national allocation policy. Based on previous experience as the Chair of both the national pancreas and kidney committees of UNOS, I have been funded as a senior investigator of the Scientific Registry of Transplant Recipients (SRTR). The SRTR is contracted by the government (HRSA) to provide analysis based on the national data registry to guide policy development. Related funding during last 3 years: HSRA 75R60220C00011 (annual funding – contract to continue thru 2025).
In addition to the public policy development guided by the SRTR, I have served as the Chair of the Ethics Committee of The Transplantation Society, which guides international policies regarding the complex ethical issues involved in transplantation (see Professional Competence below).
Pancreatic Islet Transplantation
The translational research in the field of pancreatic islets revolves around clinical trials of the safety and efficacy of islet transplantation in patients with Type I diabetes. The clinical trials are funded by the National Institutes of Health (NIH) and the Juvenile Diabetes Research Foundation (JDRF). These clinical trials focus on novel immunosuppressive strategies that utilize co-stimulatory blockade to prevent the immune response against pancreatic islets with a regimen that is not toxic to kidneys or beta cells.
Related research involves improving the techniques required for isolating pancreatic islets from the pancreas, which is being conducted in a fully compliant GMP laboratory facility. The study of the alloimmune and autoimmune response following islet transplantation will be conducted to determine the efficacy of the immunosuppressive strategies. Further translational studies will include methods of expanding the source of beta cells, using direct proliferation, as well as manipulation of precursor cells localized in the adult pancreas. We are currently funded (PI) for a translational grant from California Institute of Regenerative Medicine (CIRM) to bring embryonic stem cell-derived beta cells to a clinical trial.
Solid Organ Transplantation in People with HIV
With the advent of highly active anti-retroviral therapy (HAART), HIV has been a chronic disease. People with HIV are no longer dying from progression of HIV to AIDS, but rather as a result of end stage live disease (viral hepatitis co-infection) and kidney disease (HIV nephropathy). Our laboratory heads up the large NIH-sponsored national multicenter trial which is studying the safety and efficacy of solid organ transplantation in people with HIV. Translational research is exploring the impact of HIV on organ function and the impact of immunosuppression on the immune response against HIV and associated copathogens.
Research Interests
Induction of transplantation tolerance to block alloimmunity and recurrent autoimmunity following pancreatic islet transplantation
Safety and efficacy of solid organ transplantation in people with HIV
Research Pathways
Publications
- Wait Time Advantage for Transplant Candidates With HIV Who Accept Kidneys From Donors With HIV Under the HOPE Act.| | PubMed
- Next Steps for Clinical Xenotransplantation in the United States.| | PubMed
- Expanding Access to Organ Transplant for People Living With HIV: Can Policy Catch Up to Outcomes Data?| | PubMed
- A Multi-Modal Approach to Islet and Pancreas Transplantation With Calcineurin-Sparing Immunosuppression Maintains Long-Term Insulin Independence in Patients With Type I Diabetes.| | PubMed
- The John S. Najarian symposium: The past, present, and future of surgery and transplantation, May 20, 2022, Minneapolis, MN.| | PubMed
- COVID-19 infection and vaccination rarely impact HLA antibody profile in waitlisted renal transplant candidates- a multicenter cohort.| | PubMed
- OPTN/SRTR 2021 Annual Data Report: Pancreas.| | PubMed
- The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir.| | PubMed
- Erratum.| | PubMed
- Impact of Donor Liver Macrovesicular Steatosis on Deceased Donor Yield and Posttransplant Outcome.| | PubMed